Drug intelligence / Profile preview

BioPB-01

Development stage: Unknown
Lead developer: Bio Balance
Administration: Oral

Overview

BioPB-01 is an investigational therapeutic agent developed for the management of metabolic disorders, specifically being studied in the context of obesity, overweight adults, and potentially insulin resistance. It is being evaluated in clinical studies for its impact on body weight, body composition, stool consistency, and overall safety and tolerability. The precise mechanism of action is not clearly outlined in public registries, and the molecular modality has not been definitively disclosed in available clinical trial records[1][3][5].

Brand names: BioPB-01BioPB01BioPB 01
Other names: BioPB-01BioPB01BioPB 01

Beyond the preview

Go deeper on BioPB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioPB-01.

Explore the full profile